Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Zhaoke Ophthalmology's share price is €0.258.
Zhaoke Ophthalmology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.01. Hence, Zhaoke Ophthalmology's PS Ratio for today is 36.86.
The historical rank and industry rank for Zhaoke Ophthalmology's PS Ratio or its related term are showing as below:
FRA:9FX'
s PS Ratio Range Over the Past 10 Years
Min: 9.49 Med: 36.84 Max: 80.26
Current: 37.9
During the past 7 years, Zhaoke Ophthalmology's highest PS Ratio was 80.26. The lowest was 9.49. And the median was 36.84.
FRA:9FX's PS Ratio is ranked worse than 75.85% of 936
companies
in the Biotechnology industry
Industry Median: 9.515
vs FRA:9FX: 37.90
Zhaoke Ophthalmology (FRA:9FX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Zhaoke Ophthalmology PS Ratio Related Terms
Zhaoke Ophthalmology PS Ratio Historical Data
* Premium members only.
The historical data trend for Zhaoke Ophthalmology's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zhaoke Ophthalmology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhaoke Ophthalmology PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's PS Ratio distribution charts can be found below:
* The bar in red indicates where Zhaoke Ophthalmology's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Zhaoke Ophthalmology's Share Price of today is €0.258.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Zhaoke Ophthalmology (FRA:9FX) has a PS Ratio of 36.86 as of Sep. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zhaoke Ophthalmology and its competitors. This is near median its historical median of 36.84. Over the past decade, Zhaoke Ophthalmology's PS Ratio has ranged from 9.49 to 80.26. According to the industry distribution chart, Zhaoke Ophthalmology ranks #710 out of 936 companies in the Biotechnology industry, placing it in the top 75.9%.
Is Zhaoke Ophthalmology's PS Ratio too high?
Zhaoke Ophthalmology's current PS Ratio of 36.86 is near median its 10-year median of 36.84. Over the past 10 years, this metric has ranged from a low of 9.49 to a high of 80.26. The Biotechnology industry median PS Ratio is 9.52. Zhaoke Ophthalmology's value of 36.86 is 287.4% above this industry median. Based on the distribution chart, Zhaoke Ophthalmology ranks #710 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zhaoke Ophthalmology has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Zhaoke Ophthalmology's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhaoke Ophthalmology ranks #710 out of 936 companies for PS Ratio. This places Zhaoke Ophthalmology in the lower half of its industry. The industry median PS Ratio is 9.52. Zhaoke Ophthalmology's value of 36.86 is 287.4% above this benchmark. Historically, Zhaoke Ophthalmology's own PS Ratio has ranged from 9.49 to 80.26 over the past decade. While the company's 10-year median is 36.84 vs. the industry median of 9.52, Zhaoke Ophthalmology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhaoke Ophthalmology's current PS Ratio of 36.86 is 287.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zhaoke Ophthalmology and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhaoke Ophthalmology's current PS Ratio is 36.86, which is near median its own 10-year median of 36.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhaoke Ophthalmology stock overvalued right now?
Zhaoke Ophthalmology (FRA:9FX) has a current PS Ratio of 36.86. The stock's GF Value™ is €0.27, compared to a current price of €0.26 — trading 4.4% below its estimated fair value. The current PS Ratio is 36.86, which is near median its 10-year median of 36.84 and 287.4% above the Biotechnology industry median of 9.52. Zhaoke Ophthalmology's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Zhaoke Ophthalmology (FRA:9FX), the current PS Ratio is 36.86 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhaoke Ophthalmology (FRA:9FX) Overvalued in 2026?
Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued.
The current stock price of €0.26 is trading 4.4% below its estimated GF Value™ of €0.27.
Key valuation signals for FRA:9FX:
PS Ratio: 36.86 (near median its 10-year median of 36.84)
GF Value™: €0.27 vs. price of €0.26 (4.4% below fair value)
Industry Position: 287.4% above the Biotechnology median (#710 of 936)
No single metric tells the full story. See the FRA:9FX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score
Get the complete analysis for FRA:9FX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9FX has been successfully added to your 
